A Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986231 in Participants With Varying Degrees of Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2019
Price : $35 *
At a glance
- Drugs Cimlanod (Primary)
- Indications Decompensated heart failure; Heart failure
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 23 Sep 2019 Status changed from recruiting to completed.
- 28 Jan 2019 Planned End Date changed from 26 Dec 2018 to 17 Mar 2019.
- 28 Jan 2019 Planned primary completion date changed from 25 Dec 2018 to 4 Feb 2019.